Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
November 16 2021 - 8:00AM
Business Wire
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy
company committed to cures for blood cancers and serious blood
diseases, today announced that company management will present its
corporate highlights at the following upcoming virtual investor
conferences:
- Evercore ISI 4th Annual HealthCONx Conference, November 30,
2021 with a presentation at 1:25 p.m. ET.
- Piper Sandler 33rd Annual Virtual Healthcare Conference,
December 2, 2021. Company pre-recorded fireside chat will become
available to registered conference attendees on Monday, November
22, 2021 at 10:00 a.m. ET.
- JMP Securities Hematology and Oncology Summit, December 6, 2021
with a fireside chat at 10:00 a.m. ET.
A webcast of each event will be available on the “Investors
& Media” section of Gamida Cell’s website at
www.gamida-cell.com, and will be available for at least 14 days
following the event.
About Gamida Cell
Gamida Cell is pioneering a diverse immunotherapy pipeline of
potentially curative cell therapies for patients with solid tumor
and blood cancers and other serious blood diseases. We apply a
proprietary expansion platform leveraging the properties of NAM to
allogeneic cell sources including umbilical cord blood-derived
cells and NK cells to create therapies with potential to redefine
standards of care. These include omidubicel, an investigational
product with potential as a life-saving alternative for patients in
need of bone marrow transplant, and a line of modified and
unmodified NAM-enabled NK cells targeted at solid tumor and
hematological malignancies. For additional information, please
visit www.gamida-cell.com or follow Gamida Cell on LinkedIn,
Twitter, Facebook or Instagram at @GamidaCellTx.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995, including with respect to timing of initiation and progress
of, and data reported from, the clinical trials of Gamida Cell’s
product candidates, anticipated regulatory filings (including the
submission of the BLA for omidubicel to the FDA), commercialization
planning efforts, the potentially life-saving or curative
therapeutic and commercial potential of omidubicel, and Gamida
Cell’s expectations regarding its projected cash to be used for
operating activities and cash runway. Any statement describing
Gamida Cell’s goals, expectations, financial or other projections,
intentions or beliefs is a forward-looking statement and should be
considered an at-risk statement. Such statements are subject to a
number of risks, uncertainties and assumptions, including those
related to the impact that the COVID-19 pandemic could have on our
business, and including the scope, progress and expansion of Gamida
Cell’s clinical trials and ramifications for the cost thereof;
clinical, scientific, regulatory and technical developments; and
those inherent in the process of developing and commercializing
product candidates that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around
such product candidates. In light of these risks and uncertainties,
and other risks and uncertainties that are described in the Risk
Factors section and other sections of Gamida Cell’s Annual Report
on Form 20-F, filed with the Securities and Exchange Commission
(SEC) on March 9, 2021, as amended, and other filings that Gamida
Cell makes with the SEC from time to time (which are available at
http://www.sec.gov), the events and circumstances discussed in such
forward-looking statements may not occur, and Gamida Cell’s actual
results could differ materially and adversely from those
anticipated or implied thereby. Although Gamida Cell’s
forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors
currently known by Gamida Cell. As a result, you are cautioned not
to rely on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211116005379/en/
For investors: Courtney Turiano Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com 1-212-362-1200
For media: Rhiannon Jeselonis Ten Bridge Communications
rhiannon@tenbridgecommunications.com 1-978-417-1946
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gamida Cell (NASDAQ:GMDA)
Historical Stock Chart
From Jul 2023 to Jul 2024